Overview
Lobbying Costs
10,000€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
0.1 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
ExeVir Bio (ExeVir)
EU Transparency Register
180203343227-11 First registered on 18 Jun 2021
Goals / Remit
ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit from vaccines, such as immunocompromised individuals. The versatile VHH platform enables both prevention and treatment of bacterial and viral threats.
Main EU files targeted
- EU Strategy on COVID-19 and infectious diseases Therapeutics
- A Pharmaceutical Strategy for Europe
- Horizon EuropeAddress
Head Office
Technologiepark-Zwijnaarde 94
Ghent 9052
BELGIUMEU Office
Technologiepark-Zwijnaarde 94
Ghent 9052
BELGIUMWebsite
-
People
Total lobbyists declared
1
Employment time Lobbyists 10% 1 Lobbyists (Full time equivalent)
0.1
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
ExeVir has contracted EURALIA to advise us
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Flanders Bio
MEDVIAMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
10,000€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
0€ - 10,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
None declared
Groups (European Parliament)
N/A
Communication activities
None declared
Other activities
None declared
- Meetings
Meetings
None declared
- Meetings